Soluble epoxide hydrolase drives ferroptosis and cognitive impairment in Alzheimer’s disease
Year: 2026
Type: article
Abstract: Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical mechanism in pathogenesis of Alzheimer’s disease (AD). However, the upstream regulators linking amyloid pathology to iron dyshomeostasis and redox dysfunction remain incompletely understood. Here, we identify soluble epoxide hydrolase (sEH), encoded by EPHX2 , as a key mediator of ferroptotic vulnerability in AD. Ferroptosis-related gene profiling in induced pluripotent stem cell (iPSC)–derived neural progenitor cells (NPCs) from AD patients revealed dysregulation of iron metabolism and antioxidant pathways, accompanied by elevated EPHX2 expression. In APP/PS1 mice and amyloid-β peptide (Aβ 1 - 42 )–injected mice, hippocampal sEH levels were significantly increased and correlated with iron dyshomeostasis (elevated DMT1, TfR, IRP1, and FTH1, reduced FPN) and impaired ferroptosis defense (reduced SLC7A11, GPX4, and FSP1), as well as cognitive impairment. Targeted redox metabolomics demonstrated cysteine depletion, altered glutathione (GSH/GSSG) balance, and global redox remodeling, indicating dysfunction of the SLC7A11–GSH–GPX4 axis. Pharmacological inhibition of sEH with TPPU or genetic deletion of Ephx2 restored iron homeostasis, normalized glutathione metabolism, reduced reactive oxygen species and lipid peroxidation, and ameliorated cognitive deficits. In AD patient iPSCs, and derived NPCs, sEH inhibition rescued membrane lipid peroxidation and mitigated RSL3-induced loss of cell viability, accompanied by rescued GPX4 expression, suppressed oxidative stress, and attenuated ferroptosis-associated mitochondrial damage. Collectively, these findings establish sEH as an upstream regulator linking amyloid pathology to iron dyshomeostasis, impaired antioxidant defense, and ferroptosis in AD. Targeting sEH effectively restores redox balance and protects against cognitive decline, highlighting sEH inhibition as a promising ferroptosis-based therapeutic strategy for AD.
Source: Frontiers in Immunology
Authors: Xiangge Guo(Data curation, Formal analysis, Methodology, Writing – original draft), Jingrui Liu(Data curation, Methodology, Writing – original draft), Aoyu Hu(Methodology, Writing – original draft), Hongying Zhao(Methodology, Writing – original draft), Jiaxin Wang, Fanjie Zhou(Data curation, Formal analysis, Methodology, Writing – original draft), Xumeng Wang(Data curation, Methodology, Writing – original draft), Jiaxuan Wang, Biqing Cao(Methodology, Writing – original draft), Yanting Li(Writing – original draft), Kenji Hashimoto(Conceptualization, Supervision, Writing – review & editing), Wei Shan(Conceptualization, Investigation, Supervision, Validation, Visualization, Writing – review & editing), Min Ma(Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing), Qian Ren(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing)
Institutions: Hebei Medical University, Soochow University, Third Hospital of Hebei Medical University, Chiba University, Southwest Medical University, First Affiliated Hospital of Zhengzhou University, Center for Forensic Mental Health, Chiba University, Capital Medical University, Beijing Tian Tan Hospital
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
Awards: G1381461759, G3693650732, G7696193182
OpenAlex ID: W7235215796
